Atossa Therapeutics (NASDAQ:ATOS) PT Raised to $6.50

Atossa Therapeutics (NASDAQ:ATOS) had its price objective lifted by Ascendiant Capital Markets from $6.25 to $6.50 in a research report released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of Atossa Therapeutics from a hold rating to a sell rating in a report on Monday, August 12th. HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of Atossa Therapeutics in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Atossa Therapeutics in a report on Thursday, June 20th.

Atossa Therapeutics Stock Up 1.3 %

Shares of Atossa Therapeutics stock opened at $1.52 on Wednesday. The firm has a market cap of $191.16 million, a PE ratio of -6.33 and a beta of 1.19. The business has a 50-day moving average price of $1.34 and a 200 day moving average price of $1.40. Atossa Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, sell-side analysts expect that Atossa Therapeutics will post -0.22 EPS for the current year.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Atossa Therapeutics in the 2nd quarter valued at about $29,000. Cetera Advisors LLC purchased a new position in shares of Atossa Therapeutics in the 1st quarter valued at $72,000. Virtu Financial LLC acquired a new stake in Atossa Therapeutics during the 1st quarter worth $151,000. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the second quarter valued at $161,000. Finally, Bank of New York Mellon Corp boosted its stake in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after acquiring an additional 399,041 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.